Galectin Therapeutics (US:GALT) — Company Overview, News & Financial Data
Galectin Therapeutics develops therapies targeting galectin proteins to treat fibrotic liver disease and cancers, addressing unmet needs.
Galectin Therapeutics
Galectin Therapeutics (NASDAQ:GALT) is a biotechnology company deeply involved in the development of therapies that target galectin proteins to treat fibrotic liver disease and cancer. With a primary focus on utilizing its expertise in galectin science, Galectin Therapeutics endeavors to create innovative treatments that can significantly improve the lives of patients struggling with these severe conditions. The company's key projects include the development of its flagship compound, belapectin, for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis and cirrhosis, a testament to its commitment to addressing unmet medical needs. Through its sustained research and development efforts, Galectin Therapeutics aims to establish a leading position in the field of galectin inhibitors, striving to bring breakthrough solutions from the lab to the clinic.
Snapshot
Operations
Products and/or services of Galectin Therapeutics
- NASH-RX, a clinical trial investigating a treatment for non-alcoholic steatohepatitis (NASH).
- GR-MD-02, a galectin-3 inhibitor in development for fibrotic liver disease and cancer.
- Belapectin (GR-MD-02), intended for the treatment of moderate-to-severe plaque psoriasis.
- A Phase 3 study of belapectin for the prevention of esophageal varices in NASH cirrhosis.
- Research on galectin protein inhibitors as potential treatments for autoimmune diseases and fibrosis.
Galectin Therapeutics executive team
- Mr. Joel Lewis CPAPresident, CEO & Director
- Mr. Jack W. Callicutt CPACFO, Treasurer & Corporate Secretary
- Dr. Khurram Jamil M.D.Chief Medical Officer
- Mr. Robert Tritt J.D.General Counsel
- Mr. Jim Wilkins Ph.D.Head of CMC & Pharmaceutical Development
- Ms. Beth KnowlesExecutive Assistant & Officer Manager